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Systemic Atherosclerotic Inﬂammation Following Acute Myocardial
Infarction: Myocardial Infarction Begets Myocardial Infarction
Nikhil V. Joshi, MD; Iqbal Toor, MD; Anoop S. V. Shah, MD; Kathryn Carruthers, MPhil; Alex T. Vesey, MD; Shirjel R. Alam, MD;
Andrew Sills, MD; Teng Y. Hoo; Adam J. Melville, MD; Sarah P. Langlands, MD; William S. A. Jenkins, MD; Neal G. Uren, MD;
Nicholas L. Mills, PhD; Alison M. Fletcher, PhD; Edwin J. R. van Beek, PhD; James H. F. Rudd, PhD; Keith A. A. Fox, MD;
Marc R. Dweck, PhD;* David E. Newby, DSc;*
Background-—Preclinical data suggest that an acute inﬂammatory response following myocardial infarction (MI) accelerates
systemic atherosclerosis. Using combined positron emission and computed tomography, we investigated whether this
phenomenon occurs in humans.
Methods and Results-—Overall, 40 patients with MI and 40 with stable angina underwent thoracic 18F-ﬂuorodeoxyglucose
combined positron emission and computed tomography scan. Radiotracer uptake was measured in aortic atheroma and
nonvascular tissue (paraspinal muscle). In 1003 patients enrolled in the Global Registry of Acute Coronary Events, we assessed
whether infarct size predicted early (≤30 days) and late (>30 days) recurrent coronary events. Compared with patients with stable
angina, patients with MI had higher aortic 18F-ﬂuorodeoxyglucose uptake (tissue-to-background ratio 2.150.30 versus
1.840.18, P<0.0001) and plasma C-reactive protein concentrations (6.50 [2.00 to 12.75] versus 2.00 [0.50 to 4.00] mg/dL,
P=0.0005) despite having similar aortic (P=0.12) and less coronary (P=0.006) atherosclerotic burden and similar paraspinal
muscular 18F-ﬂuorodeoxyglucose uptake (P=0.52). Patients with ST-segment elevation MI had larger infarcts (peak plasma
troponin 32 300 [10 200 to >50 000] versus 3800 [1000 to 9200] ng/L, P<0.0001) and greater aortic 18F-ﬂuorodeoxyglucose
uptake (2.240.32 versus 2.020.21, P=0.03) than those with non–ST-segment elevation MI. Peak plasma troponin
concentrations correlated with aortic 18F-ﬂuorodeoxyglucose uptake (r=0.43, P=0.01) and, on multivariate analysis, independently
predicted early (tertile 3 versus tertile 1: relative risk 4.40 [95% CI 1.90 to 10.19], P=0.001), but not late, recurrent MI.
Conclusions-—The presence and extent of MI is associated with increased aortic atherosclerotic inﬂammation and early recurrent
MI. This ﬁnding supports the hypothesis that acute MI exacerbates systemic atherosclerotic inﬂammation and remote plaque
destabilization: MI begets MI.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT01749254. ( J Am Heart Assoc. 2015;4:
e001956 doi: 10.1161/JAHA.115.001956)
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plaque
D espite recent advances, prognosis following acutemyocardial infarction (MI) remains poor1–3 because of
a considerable risk of recurrent infarction4 and ischemia.5
Such recurrent events are as likely to occur at the site of
nonculprit plaques as at the site of the original culprit lesion.6
In postmortem studies of patients dying after acute MI, there
is evidence of multiple plaque-related thrombotic events: on
average, 2.4 per patient.7 Moreover, there is an increased
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incidence of ischemic stroke following MI (not exclusively due
to embolic events), suggesting systemic and localized desta-
bilization of remote atherosclerotic plaque.8,9
MI occurs predominantly as a result of acute atheroscle-
rotic plaque rupture,3,9–11 with inﬂammation believed to be a
key precipitant.10,11 Macrophages inﬁltrate high-risk plaque
and secrete matrix metalloproteinases that weaken the
ﬁbrous cap and predispose the plaque to rupture.10,11 Recent
preclinical murine data have indicated that MI induced by
coronary artery ligation causes a systemic inﬂammatory
response that involves macrophage mobilization, a general-
ized increase in atherosclerotic inﬂammation, and accelerated
plaque progression12; however, this phenomenon has not
been observed directly in humans.
Positron emission tomography (PET) combined with com-
puted tomography (CT) allows the in vivo assessment of
atherosclerotic disease in humans. Glucose analogue 18F-
ﬂuorodeoxyglucose (18F-FDG) is taken up by cells with high
metabolic requirements. It has become a widely used as a
measure of acute vascular inﬂammation correlating with
atherosclerotic macrophage burden, response to drug ther-
apy, and symptomatic status.13–16 Its generalized uptake
within large arteries is a powerful predictor of subsequent
adverse cardiovascular events.17
In this prospective clinical trial, we determined whether
systemic atherosclerotic plaque metabolism is increased in
patients with MI compared with those with stable coronary
disease and whether this increase is more marked in those
with larger infarctions. Furthermore, we explored whether this
increase might be of clinical relevance and whether infarct
size could predict recurrent early MI.
Methods
The study comprised 2 cohorts of patients: an imaging cohort,
consisting of subjects with stable angina and MI, and an
outcome cohort, comprising patients enrolled in the Global
Registry of Acute Coronary Events (GRACE).18
Imaging Cohort
Subjects
Consecutive patients with acute ST-segment elevation MI
(STEMI), non-STEMI,19 and stable angina pectoris scheduled
for invasive coronary angiography were recruited from the
Royal Inﬁrmary of Edinburgh, as described previously.20
Patients with MI fulﬁlled the criteria for type 1 MI according
to the Universal Deﬁnition of MI.19 STEMI was deﬁned as new
ST-segment elevation at the J point in 2 contiguous leads with
the following cut points: ≥0.1 mV in all leads except V2 to V3,
for which the thresholds were ≥0.2 mV for men and
≥0.25 mV for women. Consecutive patients with stable
angina pectoris were recruited if they had typical symptoms
of exertional anginal chest pain, had previously documented
coronary artery disease (>70% stenosis of at least 1 major
epicardial coronary artery), and were scheduled for invasive
coronary angiography. Patients were excluded if they had
suffered an acute coronary syndrome within the previous
3 months.
Other exclusion criteria were age <50 years, insulin-
dependent diabetes mellitus, women of childbearing age not
taking contraception, severe renal failure (serum creatinine
>250 lmol/L), known contrast allergy, and inability to
provide informed consent. Studies were performed with the
approval of the local research ethics committee, in accor-
dance with the Declaration of Helsinki, and with the written
informed consent of each participant.
All patients underwent a comprehensive baseline clinical
assessment including evaluation of their cardiovascular risk
factor proﬁle. Blood was drawn from all participants for
evaluation of plasma C-reactive protein (CRP) concentrations,
which were measured using the Multigent CRP Vario assay
(Archi-Tech cSystems Assay; Abbott Laboratories).
PET-CT imaging
All patients underwent PET-CT imaging of the thorax with a
hybrid scanner (Biograph mCT; Siemens Medical Systems)
using 18F-FDG as well as coronary calcium scoring and CT
angiography of the aorta and coronary arteries.20–22 Subjects
were administered a target dose of 200 MBq 18F-FDG
intravenously and subsequently rested in a quiet environment
for 90 minutes. A low-dose attenuation-correction CT scan
(50 mAs, 120 keV with CARE Dose 4D) was then performed,
followed by PET imaging of the thorax, covering 1 PET bed for
20 minutes. Patients were asked to observe a low-carbohy-
drate, high-protein, and high-fat diet and to refrain from
alcohol intake for at least 24 hours prior to the 18F-FDG scan
to minimize cardiac uptake.
Following acquisition of the PET data, an electrocardio-
gram-gated breath-hold CT scan (non–contrast enhanced,
40 mAs/rotation, 120 kV; Siemens Medical Systems) was
performed for calcium scoring. CT angiography was per-
formed immediately afterward per the standardized scanning
protocol.
Image analysis
Anonymized PET-CT data sets were presented in a random
order on an OsiriX workstation (64 bit; version 5.5.1; OsiriX
Imaging Software) to trained observers (N.V.J., A.S.) who were
blinded to the patients’ clinical status.18 To aid image
analysis, PET images were fused with the CT angiograms,
and regions of interest were drawn around the thoracic aorta
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on serial 3-mm axial slices. Within these regions, mean and
maximum tracer activities were measured using standard
uptake values and corrected for blood-pool activity in the
superior vena cava to provide tissue-to-background ratios
(TBRs).20–24 The ascending aorta was deﬁned as the segment
of the aorta from the lower level of the right pulmonary artery
up to the last slice at which the aorta maintained its circular
cross-sectional appearance. The descending aorta was
deﬁned similarly as the region extending up from the tip of
the diaphragm to the last circular slice. The aortic arch was
deﬁned as the region of aorta connecting the ascending and
descending aortas (Figure 1). Aortic radiotracer uptake was
quantiﬁed using the method of Fayad et al.25 In brief, the
following measures of uptake were measured on axial slices
across the aorta as a whole and within each region: TBRmax,
the average of the maximum TBR values measured on each
axial slice; TBRmean, the average of the mean TBR values
measured on each slice; max TBR, the maximum uptake TBR
value in any axial section; and TBRMDS, the most diseased
segment, deﬁned as the highest maximal TBR value averaged
over 3 consecutive slices.25 Thirty patients were selected
randomly to test the repeatability of 18F-FDG measurements
in the aorta. Fifteen patients from each cohort were selected,
and 2 trained readers (N.V.J., S.P.L.) quantiﬁed aortic activity
independently. Activity within nonvascular tissue was
assessed using oval-shaped regions of interest drawn within
paraspinal muscle (area 7 cm2) on 5 consecutive axial
slices.
CT analysis was performed on a dedicated cardiovascular
workstation (Vitrea; Vital Images). Vessel-speciﬁc and total
Agatston calcium scores were calculated, as described
previously,21 for the coronary arteries, the aorta, and its
different regions using a threshold of 130 Hounsﬁeld units.26
Outcome Cohort
Full details of the GRACE methods have been published
previously.27,28 The Edinburgh cohort of the prospectively
maintained GRACE database was used to identify 1003
patients admitted with an acute coronary syndrome between
January 20, 2003, and June 9, 2009.29 To be eligible, patients
(aged >18 years) had to be admitted with an acute coronary
syndrome as a presumptive diagnosis and had to have at least
1 of the following conditions: electrocardiographic changes
consistent with acute coronary syndrome, serial increases in
biomarkers of cardiac necrosis, or documented coronary
artery disease. For consistency, only patients who had plasma
troponin I concentrations quantiﬁed (Abbott Laboratories) in a
standardized accredited laboratory were included. Exclusion
criteria were secondary myocardial injury precipitated or
accompanied by a signiﬁcant comorbidity, trauma, or surgery.
Information regarding patient demographic characteristics,
medical history, timing and occurrence of acute coronary
symptoms, clinical characteristics, electrocardiographic ﬁnd-
ings, treatment approaches, and in-hospital outcomes was
collected through completion of a standardized proforma.27,28
The baseline and peak troponin I concentrations during
admission were recorded, and patients were placed in tertiles
based on their peak troponin I to reﬂect the degree of
myocardial injury and the size of their infarct.30
The primary end point of the analysis was early recurrent
MI following the index admission, deﬁned as recurrent type 1
MI within 30 days of index admission.18 To avoid confounding
with the index presentation, only those patients having
recurrent MI beyond the ﬁrst 24 hours after presentation
were analyzed, as described previously.18 We also examined
the factors associated with late recurrent MI as an exploratory
end point, deﬁned as a recurrent type 1 MI >30 days
following index admission.
Statistical Analysis
As a prespeciﬁed end point of our previously reported trial
(ClinicalTrials.gov identiﬁer NCT01749254),20 we explored
18F-FDG uptake in remote aortic atheroma of patients with
recent MI or stable coronary heart disease. Continuous data
were tested for normality with the D’Agostino and Pearson
omnibus test. Continuous parametric variables were
expressed as meanSD and compared using Student t tests.
Nonparametric data were presented as median (interquartile
range [IQR]) and compared using the Mann–Whitney U test or
the Wilcoxon signed rank test, as appropriate. Interobserver
reproducibility was calculated by the Bland–Altman method
and intraclass correlation coefﬁcients with 95% CIs. The
Fisher exact test or the chi-square test was used for analysis
of categorical variables. Correlation of parametric data was
A
B
C
Figure 1. Measurement of radiotracer uptake in the aorta. The
aorta was segmented into ascending aorta (A), arch of aorta (B),
and descending aorta (C), as shown. Regions of interest were
drawn around the aorta on axial slices to provide measures of
radiotracer uptake.
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assessed using the Pearson correlation coefﬁcient, and
the Spearman rank correlation was used for nonparametric
data.
Patients in the registry cohort were placed in tertiles
according to their peak troponin concentration. Kaplan–Meier
curves were used to estimate the distribution of early
recurrent MI across the tertiles. Univariate analysis was
undertaken to identify associations with early (≤30 days) and
late (>30 days) recurrent MI that were then entered into the
multivariate logistic regression model based on a univariate
association of P<0.1. In addition, age and sex were included in
the model. Statistical analysis was performed with GraphPad
Prism version 6 (GraphPad Software Inc) and SPSS 19.0 (IBM
Corp), as appropriate. Unless stated, a 2-sided P<0.05 was
considered statistically signiﬁcant.
Results
Imaging Cohort
Overall, 40 patients with stable angina and 40 with MI
underwent 18F-FDG PET imaging. The median time between
hospitalization and 18F-FDG PET imaging was 11 days (IQR 8
to 17 days) in patients with MI. Compared with patients with
stable angina, patients with MI were younger, had less
extensive coronary artery disease (Table 1), and had lower
coronary artery calcium scores (coronary artery calcium
score: stable angina 599 Agatston units [AU; IQR 60 to 1302
AU]; MI 159 AU [IQR 42 to 456 AU]; P=0.006) (Tables 1 and
2). Although apparently higher aortic calcium scores were
noted in patients with stable angina, this difference did not
reach statistical signiﬁcance (aortic calcium scores; stable
angina 538 AU [IQR 4 to 1870 AU]; MI 135 AU [IQR 0 to 805
AU]; P=0.12) (Table 2).
Positron emission tomography
The reproducibility of TBR measurements in the aorta for
tracer activity was excellent, with no ﬁxed or proportional
biases and with narrow limits of agreement (Table S1). In
contrast to the calcium scores, 18F-FDG uptake was 20%
higher in the aortas of patients with recent MI than those with
stable coronary artery disease (Table 2 and Figure 2). This
ﬁnding was consistent in all regions of the aorta assessed
(entire thoracic aorta, ascending aorta, aortic arch, descend-
ing aorta; all P<0.0001) and with all measures of tracer
activity (mean TBRmax, mean TBRmean, max TBR, TBRMDS, all
P<0.001). Furthermore, 18F-FDG activity was higher in
patients with STEMI compared with those with non-STEMI
(TBRmax 2.240.32 versus 2.020.21, respectively; P=0.03)
(Table 2), consistent with the former having sustained larger
MIs (peak plasma troponin concentration 32 300 ng/L [IQR
10 200 to >50 000 ng/L] versus 3800 ng/L [IQR 1000 to
9200 ng/L]; P<0.0001). Indeed, aortic 18F-FDG activity
correlated with peak plasma troponin I concentrations
(r=0.43, P=0.01).
In patients with stable angina and those with MI, paraspinal
uptake of 18F-FDG (mean TBRmax 0.790.25 versus
0.750.21, respectively; P=0.52) was similar.
C-reactive protein
Compared with patients with stable angina, patients with MI
had higher plasma CRP concentrations (6.50 mg/dL [IQR
2.00 to 12.75 mg/dL] versus 2.00 mg/dL [IQR 0.50 to 4.00
mg/dL], P=0.0005). Among patients with MI, patients with
STEMI appeared to have higher plasma CRP concentrations
(7.50 mg/dL [IQR 2.00 to 13.75 mg/dL] versus 2.50 mg/dL
[IQR 1.75 to 9.50 mg/dL]), but this difference did not reach
statistical signiﬁcance (P=0.22). There was a modest corre-
lation between peak troponin I concentrations and CRP
(r=0.35, P=0.03).
Outcome Cohort
A total of 1003 patients enrolled in the GRACE database were
followed for a median follow-up period of 34 months (IQR 18
to 50 months). Early recurrent MI occurred in 54 patients
following index admission, whereas late recurrent MI occurred
in 89 patients.
Patients were classiﬁed into tertiles according to their
peak plasma troponin I concentrations measured during the
index admission (tertile 1, ≤220 ng/L; tertile 2, 230 to
6130 ng/L; and tertile 3, ≥6140 ng/L) (Table 3). On
univariate analysis, the risk of early recurrent infarction
(≤30 days) was >4-fold higher among patients in the
highest troponin tertile compared with the lowest, whereas
risk was doubled in the middle tertile compared with the
lowest (Table 4 and Figure 3). The variables with univariate
association of P<0.1 were Killip score ≥2, ST-segment
deviation, multivessel disease, and troponin I concentra-
tions. On multivariate analysis, troponin emerged as an
independent predictor of early MI after adjustment for other
relevant variables (tertile 3 versus 1: relative risk 4.40
[95% CI 1.90 to 10.19], P=0.001; tertile 2 versus 1: relative
risk 2.63 [95% CI 1.08 to 6.38], P=0.03). The only other
independent predictor was Killip class 2 (1.86 [95% CI
1.06 to 3.24], P=0.03).
In contrast, recurrent late MI was not associated with
troponin tertiles on univariate analysis (tertile 2 versus 1:
relative risk 1.07 [95% CI 0.64 to 1.79], P=0.79; tertile 3
versus 1: relative risk 0.80 [95% CI 0.46 to 1.39], P=0.43) but
rather was more closely related to traditional predictors of MI
(Table 4).
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Discussion
Using 18F-FDG PET imaging, in patients with recent MI, we
demonstrated increased metabolic activity in remote aortic
atherosclerotic plaques that correlated with the degree of
myocardial necrosis and exceeded that observed in patients
with stable coronary disease who had a greater atheroscle-
rotic burden. Using the GRACE registry, we explored the
Table 1. Baseline Characteristics of Patients With Coronary Artery Disease
Patients With Stable Angina Patients With MI
All (n=40) All (n=40) STEMI (n=26) NSTEMI (n=14)
Age, y 678 628 639 608
Male sex 36 (90) 37 (93) 24 (92) 13 (93)
BMI, kg/m2 305 285 275 304
Antecedent angina (active) 40 (100) 9 (23) 5 (19) 4 (29)
Heart rate, beats/min* 599 567 567 567
Systolic blood pressure, mm Hg 13414 13221 13120 12121
Diastolic blood pressure, mm Hg 7710 769 769 768
Cardiovascular history
Previous MI 15 (38) 5 (13) 1 (4) 4 (29)
Previous CVA/TIA 4 (10) 2 (5) 1 (4) 1 (7)
Previous PCI 19 (48) 5 (13) 2 (8) 3 (21)
Previous CABG 11 (28) 2 (5) 2 (8) 0
Risk factors
Smoking habit (ex or current) 24 (60) 25 (63) 19 (73) 6 (43)
Diabetes mellitus 13 (33) 8 (20) 7 (27) 1 (7)
Hypertension 36 (90) 17 (43) 11 (42) 6 (43)
Hypercholesterolaemia 39 (98) 19 (48) 11 (42) 8 (57)
Medications†
Aspirin 33 (83) 40 (100) 26 (100) 14 (100)
Clopidogrel 5 (13) 39 (98) 25 (96) 14 (100)
Statin 36 (90) 39 (98) 26 (100) 13 (93)
b-blocker 28 (70) 32 (80) 20 (77) 12 (86)
ACEI/ARB 20 (50) 35 (88) 25 (96) 10 (71)
Calcium channel blockers 16 (40) 2 (5) 2 (8) 0
Other antihypertensive 6 (15) 3 (8) 1 (4) 2 (14)
Oral nitrates 15 (38) 1 (3) 0 1 (7)
Serum biochemistry
Cholesterol, mg/dL 15131 18146 18150 18543
HDL-cholesterol, mg/dL 4312 4312 4312 3912
LDL-cholesterol, mg/dL 8127 11243 10843 12039
Triglycerides, mg/dL 6227 6231 6627 5827
Creatinine, mg/dL 0.960.26 0.960.30 0.970.33 0.930.27
Peak troponin concentration, ng/L (IQR) — 11 200 (3300 to >50 000) 32 300 (10 200 to >50 000) 3800 (1000 to 9200)
Data are shown as meanSD or number (percentage) except as noted. ACEI indicates angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index;
CABG, coronary artery bypass grafting; CTCA, computed tomography coronary angiography; CVA, cerebrovascular accident; HDL, high-density lipoprotein; IQR, interquartile range; LDL,
low-density lipoprotein; MI, myocardial infarction; NSTEMI, non–ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation
myocardial infarction; TIA, transient ischemic attack.
*Heart rate at the time of CTCA.
†Medications at the time of scan.
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clinical relevance of these ﬁndings to assess whether infarct
size and the associated increase in atherosclerotic inﬂamma-
tion could predict recurrent coronary atherothombotic events
in everyday clinical practice. Intriguingly, patients with the
largest infarcts had a >4-fold increase in the risk of early
recurrent MI, with baseline tertiles of plasma troponin
concentration emerging as an independent predictor of these
events. Consequently, we provided clinical data to support the
hypothesis that MI exacerbates systemic atherosclerotic
inﬂammation, destabilizes remote atheromatous plaque, and
causes an increase in early recurrent atherothrombotic
events.
Preclinical data have indicated that MI induces a macro-
phage-driven proinﬂammatory state31 that directly increases
inﬂammation in remote atheroma and induces further
atherosclerosis.12,32,33 In a mouse model, MI induced by
coronary artery ligation increased splenic monocyte motil-
ity,12 with these cells exiting the spleen en masse and
migrating both to the injured myocardium and, crucially, to
remote atherosclerotic plaque.34 In addition, sympathetic
stimulation following infarction increased the production and
liberation of hematopoietic stem and progenitor cells from the
bone marrow, resulting in further increases in circulating
monocytes and the accumulation of macrophages within
regions of remote atheroma.12 The net result was a marked
accumulation of macrophages in remote atherosclerotic
plaque following MI that resulted in acceleration of the
disease process in these areas. The ﬁrst aim of the current
Table 2. Aortic Calcium Scores and 18F-FDG Tissue-to-Background Ratios in Patients With Stable Angina and Myocardial
Infarction
Patients With Stable Angina
(n=40)
Patients With Myocardial
Infarction (n=40) P Value
Patients With STEMI
(n=26)
Patients With NSTEMI
(n=14) P Value
CT aortic calcium
Agatston units (IQR) 538 (4 to 1870) 135 (0 to 805) 0.12 183 (0 to 377) 55 (0 to 2523) 0.91
Volume, mm3 (IQR) 532 (7 to 1718) 149 (0 to 717) 0.12 192 (0 to 387) 94 (0 to 2263) 0.85
Mass, mg (IQR) 131 (2 to 517) 31 (31 to 1415) 0.07 131 (2 to 517) 43 (0 to 86) 0.90
18F-FDG
Thoracic aorta mean
TBRmax
1.840.18 2.150.30 <0.0001 2.240.32 2.020.21 0.03
Thoracic aorta mean
TBRmean
1.410.14 1.600.17 <0.0001 1.510.16 1.660.17 0.01
Thoracic aorta max TBR 2.220.31 2.640.52 <0.0001 2.780.57 2.400.35 0.02
Thoracic aorta TBRMDS 2.110.23 2.540.49 <0.0001 2.660.53 2.340.33 0.04
Aortic subregions
Ascending aorta mean
TBRmax
1.840.20 2.210.35 <0.0001 2.350.35 2.030.26 0.01
Arch of aorta mean
TBRmax
1.880.22 2.260.34 <0.0001 2.350.35 2.110.26 0.03
Descending aorta mean
TBRmax
1.820.18 2.100.30 <0.0001 2.170.32 1.980.21 0.08
18F-FDG, 18F-ﬂuorodeoxyglucose; CT, computed tomography; IQR, interquartile range; max TBR, highest value tissue-to-background ratios in any axial slice; mean TBRmax, average of the
maximum tissue-to-background ratios across all slices in the segment; mean TBRmean, average of the mean tissue-to-background ratios for all slices in the segment; NSTEMI, non–ST-
segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; TBRMDS, tissue-to-background ratio in the most diseased segment.
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Figure 2. Uptake of 18F-FDG by aortic atherosclerosis in
patients with stable and unstable coronary heart disease. Aortic
mean of the maximum tissue-to-background ratio for 18F-FDG
uptake in patients with stable angina, STEMI, and NSTEMI. Mean
with 95% CI. 18F-FDG indicates 18F-ﬂuorodeoxyglucose; NSTEMI,
non–ST-segment elevation myocardial infarction; STEMI, ST-
segment elevation myocardial infarction.
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study was to test whether this proinﬂammatory phenomenon
also occurred in humans, using 18F-FDG as a marker of
vascular macrophage inﬂammatory activity. Because we could
not measure 18F-FDG uptake before and after MI, we
prospectively compared uptake between patients with stable
coronary heart disease and those with recent MI.18 Despite a
comparable or lower overall aortic and coronary plaque
burden, aortic 18F-FDG uptake was 20% higher in patients
who had sustained a recent MI. Indeed, the aortic 18F-FDG
uptake was consistently increased across all regions of the
thoracic aorta. In contrast, paraspinal muscle uptake was
similar between the cohorts, indicating a speciﬁc vascular and
atherosclerotic response rather than generalized nonspeciﬁc
inﬂammation across all tissues. Based on clinical factors and
peak plasma troponin concentration, patients with STEMI had
larger infarcts and demonstrated greater increases in aortic
Table 3. Baseline Characteristics of Patients From the GRACE Cohort
Tertile 1 (n=332) Tertile 2 (n=336) Tertile 3 (n=335) P Value
Peak troponin I, range ≤220 230 to 6130 ≥6140 —
Age, y 6512 6612 6313 0.02
GRACE score 12447 19749 21841 <0.0001
Male sex 212 (63.9) 226 (67.3) 254 (75.8) 0.003
Smoking habit 214 (64.5) 243 (72.3) 235 (70.1) 0.08
Previous MI 149 (44.9) 91 (27.1) 51 (15.2) <0.0001
Killip score ≥2 82 (24.7) 114 (33.9) 98 (29.3) 0.03
Previous CABG 61 (18.4) 25 (7.4) 12 (3.6) <0.0001
Previous heart failure 26 (7.8) 25 (7.4) 13 (3.9) 0.07
Diabetes 53 (16.0) 47 (14.0) 47 (14.0) 0.71
ST-segment deviation 77 (23.2) 142 (42.3) 275 (82.1) <0.0001
Multivessel disease 92 (27.7) 141 (42.0) 125 (37.3) <0.0001
Recurrent MI ≤30 days 7 (2.1) 18 (5.4) 29 (8.7) 0.001
Data are shown as meanSD or number (percentage). CABG, coronary artery bypass grafting; GRACE, Global Registry of Acute Coronary Events; MI, myocardial infarction.
Table 4. Univariate Predictors of Early (≤30 Day) and Late (>30 Day) Recurrent MI
Early (≤30 Day) Recurrent MI P Value Late (>30 Day) Recurrent MI P Value
Age, y 1.02 (0.99 to 1.04) 0.14 1.04 (1.02 to 1.06) <0.0001
Male sex 1.30 (0.70 to 2.43) 0.45 0.89 (0.56 to 1.41) 0.63
Smoker 0.82 (0.46 to 1.46) 0.55 1.04 (0.65 to 1.67) 0.91
Previous MI 0.69 (0.36 to 1.32) 0.28 3.81 (2.43 to 5.95) <0.0001
Killip score ≥2 1.86 (1.06 to 3.24) 0.03 1.79 (1.14 to 2.82) 0.01
Previous CABG 0.94 (0.37 to 2.42) 0.99 2.91 (1.66 to 5.10) <0.0001
Previous heart failure 0.86 (0.26 to 2.82) 0.99 2.77 (1.40 to 5.45) 0.008
Diabetes 0.72 (0.30 to 1.71) 0.56 1.41 (0.80 to 2.48) 0.27
ST-segment deviation 1.81 (1.03 to 3.19) 0.05 1.18 (0.76 to 1.82) 0.50
Multivessel disease 1.73 (0.99 to 2.99) 0.06 1.57 (1.01 to 2.44) 0.05
Troponin tertiles
Tertile 2 vs tertile 1 2.63 (1.08 to 6.38) 0.03 1.07 (0.64 to 1.79) 0.79
Tertile 3 vs tertile 1 4.40 (1.90 to 10.19) 0.001 0.80 (0.46 to 1.39) 0.43
Linear trend across tertiles — <0.0001 — 0.57
Data are shown as relative risk (95% CI). CABG, coronary artery bypass grafting; MI, myocardial infarction.
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18F-FDG uptake than those with non-STEMI. We observed
good correlation between peak plasma troponin I concentra-
tions and aortic 18F-FDG activity, suggesting that the
association may be causal.
Next we investigated whether the observed increases in
vascular inﬂammatory activity were of clinical importance in
actual practice. Our imaging cohort was not large enough
to address this question, so we turned to data from the
well-established GRACE registry. In >1000 patients, we
demonstrated that the size of the initial MI emerged as an
independent predictor of early recurrent MI over and above
traditional risk factors, with a 4-fold increase in these
events among those with the biggest infarcts. This ﬁnding
indicates that the increased vascular inﬂammation associ-
ated with MI translates into adverse clinical events, perhaps
due to plaque destabilization and the associated increased
risk of rupture. Interestingly, our data also suggest that the
clinical effects of this systemic inﬂammatory response are
only transitory, with no association between infarct size and
later recurrent events after 30 days, by which time the
inﬂammation will have subsided and plaques begun to
stabilize once more. Our data are also consistent with
those of the smaller (n=378) Evaluation of MCC-135 for
Left Ventricular Salvage in Acute Myocardial Infarction
(EVOLVE) randomized controlled trial,35 which also observed
an increased early event rate in patients in the highest
tertile of troponin concentration, with a trend for an
increase in recurrent MI. Our ﬁndings are supported by
recently reported studies.36–39 Patients with acute coronary
syndromes have increased plaque vulnerability in nonculprit
lesions, with increased incidence of thin-capped ﬁbroath-
eromas and adherent thrombus.39 Furthermore, patients
with STEMI have accelerated plaque progression in noncul-
prit lesions on follow-up angiography,37 whereas stenting of
such lesions at the same time as culprit lesions reduces
adverse cardiovascular events.38 Moreover, patients with
unstable coronary disease have higher metabolic carotid
plaque activity compared with patients with stable disease,
suggesting a panvascular inﬂammatory process, as indi-
cated by our study.36
Taken together, our data offer clear support for the
hypothesis that MI begets early recurrent MI due to upreg-
ulated macrophage-mediated inﬂammation in remote athero-
sclerotic plaque. It would also offer an explanation for the
increased incidence of ischemic stroke following MI and
would explain why immediate reperfusion for STEMI and the
resultant limitation in myocardial injury confer greater reduc-
tion in the risk of recurrent events than revascularization after
infarct completion.10,40
Although our data support the hypothesis that MI results
in remote arterial inﬂammation, it could also be argued that
more widespread and intense atherosclerotic inﬂammation
occurs prior to the precipitation of MI and that this is the
explanation for the association. The correlation between
infarct size and the inﬂammatory signal would support the
former explanation; however, to resolve this issue, 18F-FDG
imaging would be required both before and after MI, which,
given the unpredictable nature of these events, is extremely
challenging in the clinical context. We also acknowledge
that we did not directly measure MI size and used peak
plasma troponin concentration as a surrogate measure;
however, peak plasma troponin concentration has a strong
correlation with infarct size (r=0.740, P<0.001)30,35 and is a
valid surrogate marker, especially when applied to large
data sets such as the registry cohort used in this study.
Finally, we were unable to measure systemic markers of
inﬂammation such as CRP in our outcome cohort; however,
CRP is well known to correlate with troponin release after
MI,41–43 and indeed this was observed in our imaging
cohort.
In summary, we demonstrated that the presence and
extent of MI are associated with increased aortic atheroscle-
rotic inﬂammation and early recurrent MI, supporting the
hypothesis that MI begets MI in humans.
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Figure 3. Kaplan–Meier curves demonstrating survival free from
early recurrent myocardial infarction at 30 days. Patients were
placed in tertiles according to their peak plasma troponin I
concentrations (tertile 1, ≤220 ng/L; tertile 2, 230 to 6130 ng/L;
tertile 3, ≥6140 ng/L).
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